Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 22005D0131

    Decision of the EEA Joint Committee No 131/2005 of 21 October 2005 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement

    OJ L 14, 19.1.2006, p. 18–19 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)

    ⏵This document has been published in a special edition(s) (BG, RO, HR)

    Legal status of the document In force

    ELI: http://data.europa.eu/eli/dec/2005/131(2)/oj

    19.1.2006   

    EN

    Official Journal of the European Union

    L 14/18

    DECISION OF THE EEA JOINT COMMITTEE

    No 131/2005

    of 21 October 2005

    amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement

    THE EEA JOINT COMMITTEE,

    Having regard to the Agreement on the European Economic Area, as amended by the Protocol adjusting the Agreement on the European Economic Area, hereinafter referred to as ‘the Agreement’, and in particular Article 98 thereof,

    Whereas:

    (1)

    Annex II to the Agreement was amended by Decision of the EEA Joint Committee No 116/2005 (1).

    (2)

    Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (2) is to be incorporated into the Agreement.

    (3)

    Regulation (EC) No 273/2004 repeals Council Directive 92/109/EEC (3), which is incorporated into the Agreement and which is consequently to be repealed under the Agreement,

    HAS DECIDED AS FOLLOWS:

    Article 1

    Chapter XIII of Annex II to the Agreement shall be amended as follows:

    1.

    The following point shall be added after point 15w (Directive 2004/23/EC of the European Parliament and of the Council):

    ‘15x.

    32004 R 0273: Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors (OJ L 47, 18.2.2004, p. 1).

    The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

    (a)

    The text of Article 11(2) shall not apply.

    (b)

    In Article 15 a reference is made to the Committee set up by Article 10 of Regulation (EEC) No 3677/90. When that Committee deals with matters covered by this Regulation the EFTA States shall participate fully in the work of the Committee, but shall not have the right to vote.’

    2.

    The text of point 15f (Council Directive 92/109/EEC) shall be deleted.

    Article 2

    The text of Regulation (EC) No 273/2004 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.

    Article 3

    This Decision shall enter into force on 22 October 2005, provided that all the notifications under Article 103(1) of the Agreement have been made to the EEA Joint Committee (*1).

    Article 4

    This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.

    Done at Brussels, 21 October 2005.

    For the EEA Joint Committee

    The President

    HSH Prinz Nikolaus von LIECHTENSTEIN

    (1)   OJ L 339, 22.12.2005, p. 18.

    (2)   OJ L 47, 18.2.2004, p. 1.

    (3)   OJ L 370, 10.12.1992, p. 76.

    (*1)  No constitutional requirements indicated.

    Top